Roivant Sciences (ROIV) 10-Q2023 Q1 Quarterly report

Filed: 14 Aug 23, 7:28am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. senior Avg

New words: accretive, artificial, attached, Bio, Chapter, clearance, codified, concurrently, Crohn, deceptive, deepen, disposition, Divestiture, Dosage, epidemic, FTC, heading, immunoglobulin, Importantly, indefinite, Indiana, inflammation, intelligence, Iowa, Ireland, Jersey, language, macroeconomic, MAD, mediated, moderate, Montana, Mvant, Nevada, Northern, OECD, Oregon, Parliament, plausible, principle, prioritize, RCW, risky, Russian, SAD, SDNY, sector, Sept, simplify, sNDA, successor, surrendering, survey, TAHOE, Telavant, Tennessee, ThermoFisher, tool, top, unexercised, usage, virtue, Washington, Windsor, workforce, young

Removed: abeyance, accelerate, advisor, afflicted, agile, alliance, alter, ambiguity, amending, amendment, animal, assimilation, assumed, bearing, bifunctional, big, biology, blue, booster, built, buy, call, cancer, Cantor, capitalization, card, Chairman, conditioned, confer, contemplated, contradicted, contrary, convert, converted, coordinating, counterparty, covalent, CST, curing, declining, dedicated, deep, degradation, degrade, deploy, deposit, detailed, dispersed, distracting, diverted, divesting, earn, economy, effected, emergence, engine, entirety, entrepreneurial, exempt, extensively, fell, Fitzgerald, formation, founder, founding, geographically, heard, holding, home, hospital, house, incremental, inefficiency, infection, informed, interruption, lab, labeling, legally, mission, mistake, ML, modern, modular, monetization, Myovant, negotiating, nominal, onset, overlapping, par, participating, people, pharma, pharmacological, powered, protein, QUAISAR, Ramaswamy, ratio, recommended, remanded, repay, repeal, residence, resurgence, retroactive, retroactively, returning, revoke, selectively, send, serving, showed, silico, Sio, sky, sourcing, spirit, split, staffing, standby, strain, subdivision, Sumitomo, Suzhou, talent, thereunder, titled, transformative, transit, underemployment, unemployment, unexpired, uninsured, unproven, upside, urged, vacated, vaccination, visitor, Vivek, waived, weak, weakened, wet, workplace

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated ROIV transcripts

ROIV similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Richard Pulik, Principal Financial Officer of Roivant Sciences Ltd. (the “Company”), hereby certifies that, to the best of his knowledge:

1.	The Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2023, to which this Certification is attached as Exhibit 32.2 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

2.	The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: August 14, 2023

	/s/ Richard Pulik
	Richard Pulik
	Principal Financial Officer

A signed original of this written statement required by Section 906 of 18 U.S.C. § 1350 has been provided to the Company, and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.